All In Biotech

Drug Trial Radar · NCT06178055

A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO)

A Phase 2, Double-masked, Randomized, Sham-controlled, Multiple-dose Study of the Efficacy and Safety of Intravitreal KUS121 in the Treatment of Non-Arteritic Central Retinal Artery Occlusion (CRAO)

Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

17

Actual

Start

Apr 16, 2024

Primary completion

Mar 3, 2025

Study completion Nov 30, 2025

Sponsor

Sponsor type
Industry
First posted
Dec 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Central retinal artery occlusion (CRAO) is an ophthalmologic emergency which leads to severe and permanent vision loss. There is no evidence-based therapy for CRAO. The objective of this GION study is to evaluate the efficacy and safety of KUS121 intravitreal (IVT) injection in participants with acute non-arteritic CRAO.

Conditions

  • Central Retinal Artery Occlusion

Interventions

  • KUS121 high doseDrug

    Participants will receive KUS121 high dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).

  • KUS121 low doseDrug

    Participants will receive KUS121 low dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).

  • Sham procedureDrug

    Participants will receive a sham procedure that mimics an intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of study eyes which achieve a gain of 15 ETDRS letters or more in BCVA at Week 12 compared to baselineTime frame: At baseline, Week 12

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • The Retina Partners

    Encino, California

  • Salehi Retina Institute, Inc

    Huntington Beach, California

  • Kaiser Permanente Oakland Med Ctr.

    Oakland, California

  • Florida Retina Institute

    Jacksonville, Florida

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland

  • Kresge Eye Institute/Wayne State University

    Detroit, Michigan

  • NYEE Infirmary of Mount Sinai

    New York, New York

  • UH Eye Institute

    Cleveland, Ohio

  • Austin Retina Associates

    Austin, Texas

  • Retina Consultants of Texas

    San Antonio, Texas

  • Retina Consultants of Texas

    The Woodlands, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.